Share

December 02, 2014; 83 (23) Article

Results of 2-year vitamin B treatment on cognitive performance

Secondary data from an RCT

Nikita L. van der Zwaluw, Rosalie A.M. Dhonukshe-Rutten, Janneke P. van Wijngaarden, Elske M. Brouwer-Brolsma, Ondine van de Rest, Paulette H. In 't Veld, Anke W. Enneman, Suzanne C. van Dijk, Annelies C. Ham, Karin M.A. Swart, Nathalie van der Velde, Natasja M. van Schoor, Tischa J.M. van der Cammen, André G. Uitterlinden, Paul Lips, Roy P.C. Kessels, Lisette C.P.G.M. de Groot
First published November 12, 2014, DOI: https://doi.org/10.1212/WNL.0000000000001050
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
456

Share

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective: We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cognitive performance in elderly people with elevated homocysteine (Hcy) levels.

Methods: This multicenter, double-blind, randomized, placebo-controlled trial included 2,919 elderly participants (65 years and older) with Hcy levels between 12 and 50 µmol/L. Participants received daily either a tablet with 400 µg folic acid and 500 µg vitamin B12 (B-vitamin group) or a placebo tablet. Both tablets contained 15 µg vitamin D3. Data were available for global cognitive functioning assessed by Mini-Mental State Examination (n = 2,556), episodic memory (n = 2,467), attention and working memory (n = 759), information processing speed (n = 731), and executive function (n = 721).

Results: Mean age was 74.1 (SD 6.5) years. Hcy concentrations decreased 5.0 (95% confidence interval −5.3 to −4.7) µmol/L in the B-vitamin group and 1.3 (−1.6 to −0.9) µmol/L in the placebo group. Cognitive domain scores did not differ over time between the 2 groups, as determined by analysis of covariance. Mini-Mental State Examination score decreased with 0.1 (−0.2 to 0.0) in the B-vitamin group and 0.3 (−0.4 to −0.2) in the placebo group (p = 0.05), as determined by an independent t test.

Conclusions: Two-year folic acid and vitamin B12 supplementation did not beneficially affect performance on 4 cognitive domains in elderly people with elevated Hcy levels. It may slightly slow the rate of decline of global cognition, but the reported small difference may be attributable to chance.

Classification of evidence: This study provides Class I evidence that 2-year supplementation with folic acid and vitamin B12 in hyperhomocysteinemic elderly people does not affect cognitive performance.

GLOSSARY

B-PROOF=
B-Vitamins for the Prevention of Osteoporotic Fractures;
CI=
confidence interval;
Hcy=
homocysteine;
holoTC=
holotranscobalamin;
IQR=
interquartile range;
MCI=
mild cognitive impairment;
MMSE=
Mini-Mental State Examination;
MTHFR=
methylenetetrahydrofolate reductase;
RAVLT=
Rey Auditory Verbal Learning Test;
RCT=
randomized controlled trial;
TMT=
Trail Making Test;
WU=
Wageningen University

Footnotes

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Supplemental data at Neurology.org

  • Received March 26, 2014.
  • Accepted in final form September 2, 2014.
View Full Text

AAN Non-Member Subscribers

Purchase access

Letters: Rapid online correspondence

  • B-vitamins and cognition - food for thought
    • Zoe R. Yates, University Lecturer, University of Newcastle
    • Mark Lucock, Newcastle, Australia; Emma Beckett, Newcastle, Australia; Martin Veysey, Newcastle, Australia
    Submitted December 26, 2014
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Alert Me

Recommended articles